Levitte Labs announce an LOI for the acquisition of 3 more pharmacies specializing in addiction.
INVESTOR PROFILE | Ionic Brands
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
52-Week
Range N/A
Range N/A
Current
Outstanding 108,436,715
Outstanding 108,436,715
Warrants
Options
Fully Diluted
Market Cap.
14,639,000
14,639,000
IONIC BRANDS (CSE: IONC) has a premium portfolio of cannabis concentrate consumer brands. Ionic Brands is one of the top selling concentrate company in Washington State.
Company Brief
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Highlights
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
In The News
Ionic Is Changing the Face of Cannabis and Creating a Social Revolution
It’s all in the URL: Ionic.social. “We believe our products are best when enjoyed in a social setting,” said co-founder Christian Struzan.
READ MORE
Marijuana Vaping Is The Most Explosive Growth Play In Marijuana Today
“Nobody smokes marijuana anymore, they vape it.” - New York Times That's not quite true. But it will be soon.
READ MORE
How To Invest In Marijuana Vaping
The marijuana vaporization products (or just "vape") market is set to explode in 2019.
READ MORE
Related Articles
Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials
Numinus' Montreal and Vancouver clinics will be host for an extension of the MAPS Phase III clinical trial on MDMA-assisted therapy for PTSD.
Novamind Secures Insurance Coverage for Ketamine from Four Major Payors
Novamind reports that four health insurers are now covering its ketamine treatment for Treatment-Resistant Depression.
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways surprised and disappointed the market with its Phase IIb clinical results. Despite the immediate overall selloff on the news, the outlook for many psychedelic stocks is now BETTER.
Michigan Approves Bill Expanding Access to Medical Cannabis Licenses
Michigan Gov. Gretchen Whitmer has signed legislation expanding the number of people eligible for medical cannabis licenses, including those previously barred due to a cannabis-related misdemeanor or felony.
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Compass Pathways reports successful results from its Phase IIb clinical trial of COMP360 for the treatment of Treatment Resistant Depression (TRD).